BHVN
Biohaven Ltd.
NYSE · Healthcare · Biotechnology · US
$15.69
−1.07%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.2x
Market Cap
$2.37B
MomentumView details →
1D Return
−1.07%
YTD Return
+38.22%
RSI (14)
55.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.2x
Market Cap
$2.37B
RSI (14)
55.7
MomentumView details →
1D Return
−1.07%
YTD Return
+38.22%
SummaryUpdated Jun 1, 2026
Biohaven Ltd. (NASDAQ:BHVN) is a clinical-stage biopharmaceutical company founded in 2022 as a spinoff from the original Biohaven Pharmaceutical Holding Company. The company emerged following Pfizer's acquisition of the original Biohaven's commercial migraine franchise for $11.6 billion, with the remaining pipeline assets and research programs forming the new independent entity. Biohaven focuses on developing innovative therapies for neurological and immunological diseases, positioning itself to address significant unmet medical needs in these therapeutic areas.
Similar companies
Latest newsMore news →
Biohaven entered into a licensing agreement with SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, for up to $795 million.10d agoA federal jury found Avilar Therapeutics and RA Capital willfully and maliciously misappropriated a trade secret developed at Yale, awarding Biohaven and Yale University $4 million.40d ago